Englander Institute for Precision Medicine

Publications

Found 785 results
Author Title Type [ Year(Asc)]
2024
Min D, Fiedler J, Anandasabapathy N.  2024.  Tissue-resident memory cells in antitumoral immunity and cancer immunotherapy.. Curr Opin Immunol. 91:102499.
Shah Y, Yang H, Mueller FB, Li C, Rahim SEGul, Varma E, Salinas T, Dadhania DM, Salvatore SP, Seshan SV et al..  2024.  Transcriptomic signatures of chronic active antibody-mediated rejection deciphered by RNA sequencing of human kidney allografts.. Kidney Int. 105(2):347-363.
Sternberg CN, Freedland SJ, George DJ, Morgans AK.  2024.  Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale.. Clin Genitourin Cancer. 22(6):102171.
Markowski MC, Sternberg CN, Wang H, Wang T, Linville L, Marshall CH, Sullivan R, King S, Lotan TL, Antonarakis ES.  2024.  TRIUMPH: phase II trial of rucaparib monotherapy in patients with metastatic hormone-sensitive prostate cancer harboring germline homologous recombination repair gene mutations.. Oncologist.
Newman LA, Chen Y, Martini R, Demaria S, Formenti S, Elemento O, Davis MB.  2024.  Tumor-Associated Lymphocytes and Breast Cancer Survival in Black and White Women.. JAMA Surg.
Holicek P, Guilbaud E, Klapp V, Truxova I, Spisek R, Galluzzi L, Fucikova J.  2024.  Type I interferon and cancer.. Immunol Rev. 321(1):115-127.
Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM et al..  2024.  Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.. Crit Rev Oncol Hematol. 203:104483.
Hsu J, Kim S, Anandasabapathy N.  2024.  Vaccinia Virus: Mechanisms Supporting Immune Evasion and Successful Long-Term Protective Immunity.. Viruses. 16(6)
Bensoussan Y, Elemento O, Rameau A.  2024.  Voice as an AI Biomarker of Health-Introducing Audiomics.. JAMA Otolaryngol Head Neck Surg.
de la Mora JDelgado-, Assaad MAl, Karaaslan S, Hadi K, Halima A, Deshpande A, Manohar J, Sigouros M, Medina-Martínez JS, Lieberman MD et al..  2024.  Whole genome and transcriptome analysis of pancreatic acinar cell carcinoma elucidates mechanisms of homologous recombination deficiency and unravels novel relevant fusion events.. Pathol Res Pract. 266:155798.
Kalomeris T, Assaad MAl, de la Mora JDelgado-, Gundem G, Levine MF, Boyraz B, Manohar J, Sigouros M, Medina-Martínez JS, Sboner A et al..  2024.  Whole genome profiling of primary and metastatic adrenocortical carcinoma unravels significant molecular events.. Pathol Res Pract. 266:155725.
Lukose G, Assaad MAl, Driskill JH, Levine MF, Gundem G, Semaan A, Wilkes DC, Spigland NA, Medina-Martínez JS, Sboner A et al..  2024.  Whole genome profiling of rare pediatric thoracic tumors elucidates a YAP1::LEUTX fusion in an unclassified biphasic embryonal neoplasm.. Pathol Res Pract. 264:155726.
Stephan C, Assaad MAl, Levine MF, Deshpande A, Sigouros M, Manohar J, Sboner A, Elemento O, Pavlick AC, Mosquera JMiguel.  2024.  Whole genome sequencing elucidates etiological differences in MCPyV-negative Merkel cell carcinoma.. Pathol Res Pract. 263:155668.
Assaad MAl, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, Levine MF, Gundem G, Medina-Martínez JS, Papaemmanuil E et al..  2024.  Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.. Mod Pathol. 37(4):100452.
2023
Weinstock JS, Gopakumar J, Burugula BBharathi, Uddin MMesbah, Jahn N, Belk JA, Bouzid H, Daniel B, Miao Z, Ly N et al..  2023.  Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis.. Nature. 616(7958):755-763.
Kasi PMurtaza, Afable MGeroy, Herting C, Lukanowski M, Jin Z.  2023.  Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer.. Oncologist. 28(12):1034-1048.
Vitale I, Pietrocola F, Guilbaud E, Aaronson SA, Abrams JM, Adam D, Agostini M, Agostinis P, Alnemri ES, Altucci L et al..  2023.  Apoptotic cell death in disease-Current understanding of the NCCD 2023.. Cell Death Differ. 30(5):1097-1154.
Mak L, Meleshko D, Danko DC, Barakzai WN, Maharjan S, Belchikov N, Hajirasouliha I.  2023.  Ariadne: synthetic long read deconvolution using assembly graphs.. Genome Biol. 24(1):197.
Johnson JL, Yaron TM, Huntsman EM, Kerelsky A, Song J, Regev A, Lin T-Y, Liberatore K, Cizin DM, Cohen BM et al..  2023.  An atlas of substrate specificities for the human serine/threonine kinome.. Nature. 613(7945):759-766.
Khani F, Hooper WF, Wang X, Chu TR, Shah M, Winterkorn L, Sigouros M, Conteduca V, Pisapia D, Wobker S et al..  2023.  Author Correction: Evolution of structural rearrangements in prostate cancer intracranial metastases.. NPJ Precis Oncol. 7(1):113.
Hsiehchen D, Bucheit L, Yang D, Beg MShaalan, Lim M, Lee SS, Kasi PMurtaza, Kaseb AO, Zhu H.  2023.  Author Correction: Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers.. Nat Commun. 14(1):7621.
Santambrogio L.  2023.  Autoimmunity to the modified self.. Science. 379(6637):1092-1093.
Powles T, Park SHoon, Caserta C, Valderrama BP, Gurney H, Ullén A, Loriot Y, Sridhar SS, Sternberg CN, Bellmunt J et al..  2023.  Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.. J Clin Oncol. 41(19):3486-3492.
Grivas P, Park SHoon, Voog E, Caserta C, Gurney H, Bellmunt J, Kalofonos H, Ullén A, Loriot Y, Sridhar SS et al..  2023.  Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.. Eur Urol. 84(1):95-108.
Grivas P, Grande E, Davis ID, Moon HH, Grimm M-O, Gupta S, Barthélémy P, Thibault C, Guenther S, Hanson S et al..  2023.  Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.. ESMO Open. 8(6):102050.